Dr. Reddy's Laboratories Limited (DRREDDY) — Announcement

📢 Key Event
USFDA issues Form 483 after PLI at Hyderabad biologics facility

💡 Investor Takeaway
The FDA inspection outcome may delay product launches but does not threaten long-term operations.

⚠️ Risks
Regulatory scrutiny of biologics manufacturing facility

Dr. Reddy's Laboratories announced that the USFDA completed a Pre-License Inspection at its Bachupally biologics facility in Hyderabad from June 16 to June 25, 2026, issuing a Form 483 with seven observations to be addressed within the stipulated timeline, continuing prior regulatory engagements.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This